Mechanism of Zhizi Dahuang Decoction for anti-liver injury based on network pharmacology

ZHAO Jianfeng; CHEN Kai

doi:10.7619/jcmp.20223057

Journal of Clinical Medicine in Practice > 2022 > 26(22): 83-89. > DOI: 10.7619/jcmp.20223057

ZHAO Jianfeng, CHEN Kai. Mechanism of Zhizi Dahuang Decoction for anti-liver injury based on network pharmacology[J]. Journal of Clinical Medicine in Practice, 2022, 26(22): 83-89. DOI: 10.7619/jcmp.20223057

Citation:

PDF (3663 KB)

Mechanism of Zhizi Dahuang Decoction for anti-liver injury based on network pharmacology

ZHAO Jianfeng¹,
CHEN Kai^2, ,

1.
Hospital Office, Taixing Chinese Medicine Hospital, Taixing, Jiangsu, 225400
2.
Department of Pharmacy, Taizhou School of Clinical Medicine of Nanjing Medical University, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou, Jiangsu, 225300

More Information

Received Date: October 07, 2022
Available Online: December 01, 2022

Graphical Abstract

Abstract

Abstract

Objective
To explore the potential mechanism of Zhizi Dahuang Decoction in the prevention and treatment of liver injury based on network pharmacology.
Methods
The chemical constituents of each herb in Zhizi Dahuang Decoction were retrieved from the databases and then subjected to preliminary screening; the potential action targets of Zhizi Dahuang Decoction and the therapeutic targets for liver injury were collected. After taking the intersection, the composition-target interaction was analyzed, the protein-protein interaction (PPI) network was constructed, and the key target genes were screened. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were carried out to determine the key action targets and pathways of Zhizi Dahuang Decoction in the treatment of liver injury. Finally, the binding activity of key constituents to key targets was assessed by molecular docking.
Results
A total of 71 phytochemical components were identified as potential active components from Zhizi Dahuang Decoction. A total of 47 intersection targets were generated after 341 disease-related targets were intersected with 138 compound targets. After further screening, seven key target genes of Zhizi Dahuang Decoction in the treatment of liver injury were obtained, including tumor necrosis factor (TNF), heme oxygenase-1 (HMOX1), interleukin-6 (IL6), mitogen-activated protein kinase 8 (MAPK8), prostaglandin intra peroxidase synthase 2 (PTGS2), and heat shock protein 90 alpha family class A member 1 (HSP90AA1) and Caspase 3 (CASP3). GO and KEGG pathway analysis showed that Zhizi Dahuang Decoction could reduce the level of lipid peroxidation in the liver and increase the level of antioxidant enzymes, thereby exerting an anti-oxidative stress effect; it could also play an anti-inflammatory effect by inhibiting the TNF signaling pathway. The molecular docking results showed that the three key active components in the Zhizi Dahuang Decoction had a very high binding activity to the key proteins(emodin-TNF, aloe emodin-HSP90AA1, obakunone-CASP3).
Conclusion
Zhizi Dahuang Decoction could exert its medicinal effect on liver injury by inhibiting oxidative stress, inflammatory response and hepatocyte apoptosis.
- Zhizi Dahuang Decoction,
- liver injury,
- mechanism,
- network pharmacology,
- molecular docking,
- targets

FullText(HTML)

References (18)

References

[1]	尚炽昌, 王付. 经方配伍用药指南[M]. 北京: 中国中医药出版社, 1998: 25-35.
[2]	许阳贤, 杨吉勇, 曹锦峰. 栀子大黄汤利胆抗炎作用的实验研究[J]. 江苏中医药, 2013, 15(9): 74-75. doi: 10.3969/j.issn.1672-397X.2013.09.046
[3]	陈明丽. 栀子大黄汤加减联合双歧杆菌三联活菌肠溶胶囊、蓝光照射治疗新生儿病理性黄疸的效果[J]. 医学信息, 2021, 34(24): 154-156. doi: 10.3969/j.issn.1006-1959.2021.24.040
[4]	魏雯佳, 王树民, 丁娅. 栀子大黄汤合柴胡疏肝散治疗黄疸型肝炎的临床观察[J]. 中国中医药科技, 2019, 26(4): 593-595. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY201904048.htm
[5]	杨柳, 张王宁, 刘月涛, 等. 基于网络药理学的黄芪治疗肾病综合征的机制研究[J]. 中草药, 2019, 50(8): 1828-1837. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO201908010.htm
[6]	甘丽华, 李志敏, 何泉, 等. 基于分子对接技术与网络药理学分析方法的半夏-黄连药对治疗胃食管反流病的作用机制研究[J]. 实用临床医药杂志, 2021, 25(21): 1-6. doi: 10.7619/jcmp.20211655
[7]	覃薇, 殷梓辛, 华维维, 等. 基于网络药理学和分子对接探讨通关藤治疗胃癌的作用机制[J]. 实用临床医药杂志, 2022, 26(1): 1-7, 17. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202201001.htm
[8]	褚晓文, 韩飞, 宋爱华, 等. 基于HPLC-FT-ICR MS技术的栀子大黄汤在大鼠胆汁中原形成分及代谢产物的分析鉴定[J]. 沈阳药科大学学报, 2019, 36(11): 998-1010, 1040. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYD201911008.htm
[9]	ZHU H, BI K, HAN F, et al. Identification of the absorbed components and metabolites of Zhi-Zi-Da-Huang Decoction in rat plasma by ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry[J]. J Pharm Biomed Anal, 2015, 111: 277-287. doi: 10.1016/j.jpba.2015.03.043
[10]	高雨, 朱琦, 陈蕾蕾, 等. 栀子主要有效成分的代谢及毒性研究进展[J]. 中南药学, 2021, 19(2): 254-260. https://www.cnki.com.cn/Article/CJFDTOTAL-ZNYX202102014.htm
[11]	屈义虎. 药用大黄成分分析及结合型蒽醌生物转化研究[D]. 汉中: 陕西理工大学, 2019.
[12]	刘李婷, 石菲, 刘叶, 等. 不同豆制品中大豆异黄酮的种类和含量分析[J]. 食品安全导刊, 2022(19): 100-102. https://www.cnki.com.cn/Article/CJFDTOTAL-SPAQ202219035.htm
[13]	童培珍, 李国卫, 何嘉莹, 等. 基于指纹图谱和多指标成分含量测定的枳壳与枳实药材质量差异性研究[J]. 中南药学, 2022, 20(4): 898-904. https://www.cnki.com.cn/Article/CJFDTOTAL-ZNYX202204026.htm
[14]	GADD V L, ALEKSIEVA N, FORBES S J. Epithelial plasticity during liver injury and regeneration[J]. Cell Stem Cell, 2020, 27(4): 557-573.
[15]	唐颖慧, 刘皎皎, 李粉萍, 等. 急性药物性肝损伤患者中医证候要素分布特征探讨[J]. 实用临床医药杂志, 2022, 26(7): 8-12. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202207002.htm
[16]	刘天凤, 马丽, 李艳婷, 等. 栀子大黄汤抗肝内胆汁淤积有效部位的筛选及其化学成分分析[J]. 沈阳药科大学学报, 2017, 34(8): 644-653. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYD201708006.htm
[17]	李伦, 钟伟超, 梁伟海, 等. 栀子大黄汤对四氯化碳致小鼠急性肝损伤的保护作用[J]. 中国实验方剂学杂志, 2016, 22(12): 108-112. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201612022.htm
[18]	张晓书, 韩飞, 朱鹤云, 等. 栀子大黄汤抗酒精性肝损伤的体内外实验[J]. 沈阳药科大学学报, 2016, 33(7): 565-571. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYD201607011.htm

[1]	ZHANG Qiong, LUO Qilin, WANG Kai. Application values of serum procalcitonin, anti-thrombin Ⅲ, D-dimer and four items of coagulation test in early diagnosis of pediatric sepsis[J]. Journal of Clinical Medicine in Practice, 2024, 28(21): 43-47. DOI: 10.7619/jcmp.20242011
[2]	LIU Jiaming, ZHENG Rui. Analysis in changs of coagulation function indexes in chronic obstructive pulmonary disease patients complicated with community-acquired pneumonia[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 68-71. DOI: 10.7619/jcmp.202010017
[3]	ZHAO Guiqin, GUO Zhenfeng. Correlation between fibrinogen, thrombus precursor protein and severity of coronary artery disease in patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2018, (22): 1-4. DOI: 10.7619/jcmp.201822001
[4]	ZHENG Yinglan, FAN Liqing, JIANG Shunshun. Change and significance of d-dimer, partial thrombin time and fibrinogen in patients with ulcerative colitis[J]. Journal of Clinical Medicine in Practice, 2018, (15): 41-43. DOI: 10.7619/jcmp.201815010
[5]	WU Hongli, TIAN Ruixue, YE Qing, SONG Yujia. Expressions of brain natriuretic peptide, fibrinogen,hypersensitive C-reactive protein, D-Dimer and arterial blood gas analysis in acute exacerbation of chronic obstructive pulmonary disease patients complicated with pulmonary hypertension[J]. Journal of Clinical Medicine in Practice, 2018, (3): 31-33,37. DOI: 10.7619/jcmp.201803008
[6]	ZHOU Qing, WEN Bing. Correlation between arterial blood gas analysis and serum D-dimer, fibrinogen and homocysteine in patients with COPD[J]. Journal of Clinical Medicine in Practice, 2015, (1): 26-28. DOI: 10.7619/jcmp.201501008
[7]	JIANG Hui, DU Jun, GU Jiming, GAO Qizhong, JIN Liugen, FEI Bojian. Effect comparison between laparoscopic surgery and laparotomy surgery on coagulation function in patients with gastric cancer[J]. Journal of Clinical Medicine in Practice, 2014, (17): 155-157. DOI: 10.7619/jcmp.201417054
[8]	LIU Zhanghua. Effect of prostaglandin E1 on treatment of diabetic nephropathy and its influence on plasma fibrinogen[J]. Journal of Clinical Medicine in Practice, 2014, (13): 97-98,105. DOI: 10.7619/jcmp.201413032
[9]	LIU Yuming, XU Zhiqiang, ZHOU Borong, LIU Zifan, DENG Yanhua. Relationships between antithrombin Ⅲ,protein C, fibrinogen and progressive stroke[J]. Journal of Clinical Medicine in Practice, 2013, (11): 56-58. DOI: 10.7619/jcmp.201311018
[10]	HUANG Xue-yuan, LAN Ke-ning. Changes and correlation analysis of plasma D- dimer,fibrinogen and serum high sensitivity C- reactive protein in patients with progressive cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2012, (7): 99-101. DOI: 10.3969/j.issn.1672-2353.2012.07.034

Cited By

Cited by

Periodical cited type(17)

1.	赵江华，陈云，蒋珺. 体位变换在早产新生儿呼吸窘迫综合征机械通气患儿中的应用效果. 妇儿健康导刊. 2025(04): 143-146+155 .
2.	代苗英，蓝菊红. CH50 CD3~+及CD4~+在新生儿急性呼吸窘迫综合征患儿中的表达及意义. 中国妇幼保健. 2024(01): 44-48 .
3.	周丽平，苏红. 基于集束化理念的气道分级管理在新生儿呼吸窘迫综合征机械通气患儿中的应用. 中外医学研究. 2024(16): 85-89 .
4.	牛曼玉. 预警机制联合转变体位护理在新生儿肺炎中的应用效果. 中国民康医学. 2024(14): 186-189 .
5.	胡龙，贺蛟龙，时淑娟，黄聪灵. 右美托咪定与咪达唑仑在ICU急性呼吸窘迫综合征行俯卧位通气患者中的镇静效果比较. 临床合理用药. 2024(23): 17-20 .
6.	徐海萍，潘利飞. 俯卧位通气对急性呼吸窘迫综合征患者氧合状态和谵妄发生率的影响. 中国医药导报. 2024(16): 59-61 .
7.	董惠仪，李莉，成玉萍. 早产儿俯卧位机械通气在新生儿呼吸窘迫综合征中的临床疗效分析. 婚育与健康. 2024(18): 40-42 .
8.	叶淮金. 新生儿急性呼吸窘迫综合征发病机制及俯卧位通气治疗的研究进展. 中国社区医师. 2024(26): 4-6 .
9.	林娇蓉，李科霞，许翠雯. 强化风险护理联合俯卧位通气对新生儿呼吸窘迫综合征的影响. 中国医药指南. 2024(32): 64-66 .
10.	王万旭，何学坤. 保护性机械通气治疗新生儿脓毒血症合并急性呼吸窘迫综合征效果研究. 中华养生保健. 2024(21): 56-59 .
11.	再乃甫·乃比江，艾图尼克·沙马瓦提，阿布来提·阿不都哈尔. 儿童脓毒症相关急性呼吸窘迫综合征的早期识别与治疗进展. 中国医学创新. 2024(36): 171-175 .
12.	钟艳玲，刘彦彦. 肺透明膜病新生儿经鼻持续正压通气治疗中压力不稳定发生情况及危险因素分析. 中国当代医药. 2023(08): 123-126 .
13.	汤媛. 先天性胸腔积液合并呼吸窘迫综合征1例的护理. 中国乡村医药. 2023(06): 81-82 .
14.	丘文英，林艺坤，甘跃华. 俯卧位机械通气在新生儿呼吸窘迫综合征中的临床疗效分析. 中外医疗. 2023(18): 57-60 .
15.	左园弋. 俯卧位通气在急性呼吸窘迫综合征患者中的应用价值. 婚育与健康. 2023(18): 58-60 .
16.	杜遥，张妙联，邓鸿儒. 俯卧位通气联合布地奈德应用于新生儿呼吸窘迫综合征的临床观察. 中国医学创新. 2023(34): 140-143 .
17.	李眉，陶建兰，王伏东，翟秀玲. 新生儿肺透明膜病经鼻持续正压通气治疗中通气压力不稳定风险的列线图模型构建. 实用临床医药杂志. 2023(24): 63-67 . 本站查看

Other cited types(2)

Get Citation

PDF

XML

Article views (261) PDF downloads (18) Cited by(19)

Turn off MathJax

Article Contents

Abstract

References

Mechanism of Zhizi Dahuang Decoction for anti-liver injury based on network pharmacology